Protein kinases - The major drug targets of the twenty-first century?

Nature Reviews Drug Discovery

Volumn 1, Issue 4, 2002, Pages 309-315

  Cohen, Philip ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; CANERTINIB; CEP 1347; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLOSPORIN; ERLOTINIB; EVEROLIMUS; FASUDIL; FLAVOPIRIDOL; GEFITINIB; IMATINIB; LAPATINIB; N (2 METHYLAMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; PELITINIB; PROTEIN KINASE INHIBITOR; RAPAMYCIN; ROSCOVITINE; RUBOXISTAURIN; STAUROSPORINE; TACROLIMUS; UNINDEXED DRUG; VATALANIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG EFFECT; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 0036527429     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd773     Document Type: Article

References (60)

1. Cohen, P. & Frame, S. The renaissance of GSK3. Nature Rev. Mol. Cell Biol. 2, 769-776 (2001).
2. Collett, M. S. & Erikson, R. L. Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl Acad. Sci. USA 75, 2021-2024 (1978).
3. Castagna, M. et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumour-promoting phorbol esters. J. Biol. Chem. 257, 7847-7851 (1982).
4. Kishimoto, A., Takai, Y., Mori, T., Kikkawa, U. & Nishizuka, Y. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J. Biol. Chem. 255, 2273-2276 (1980).
5. Hidaka, H., Inagaki, M., Kawamoto, S. & Sasaki, Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23, 5036-5041 (1984).
6. Shibuya, M. et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid haemorrhage. J. Neurosurg. 76, 571-577 (1992).
7. Asano, T., Ikegaki, I., Satoh, S., Seto, M. & Sasaki, Y. A protein kinase inhibitor, fasudil (AT-877); a novel approach to signal transduction therapy. Cardiovascular Drug Rev. 16, 76-87 (1998).
8. Davies, S. P., Reddy, H., Cavano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105 (2000).
9. Kimura K. et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245-248 (1996).
10. Uehata, M. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990-994 (1997).
11. 2+ dependent protein kinase. Biochem. Biophys. Res. Commun. 135, 397-402 (1986).
12. Davis, P. D. et al. Potent selective inhibitors of protein kinase C. FEBS Lett. 259, 61-63 (1992).
13. Toullec, D. et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 15771-15781 (1991).
14. Alessi, D. R. The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP-K1β (Rsk-2) and p70 S6 kinase. FEBS Lett. 402, 121-123 (1997).
15. Graves, P. R. et al. The CHK1 protein kinase and the CDC25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275, 5600-5605 (2000).
16. Fabbro, D. et al. PKC412, a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Res. 15, 17-28 (2000).
17. Engel, G. L., Farid, N. A., Faul, M. M., Richardson, F. A. & Winneroski, L. L. Salt form selection and charactensation of LY 333531 mesylate monothydrate. Int. J. Pharm. 198, 239-247 (2000).
18. Maroney, A. C. et al. CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem. 276, 25302-25308 (2001).
19. Knighton, D. R. et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 407-414 (1991).
20. Liu, J. et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66, 807-815 (1991).
21. 2+ and calmodulin-dependent protein phosphatase: probable identity with calcineurin (CaM-BP80). FEBS Lett. 137, 80-84 (1982).
22. Garber, K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J. Natl Cancer Inst. 93, 1517-1519 (2001).
23. Yu, K. et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8, 249-258 (2001).
24. Heitman, J. Mowa, N. R. & Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905-909 (1991).
25. Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumours to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314-10319 (2001).
26. +/- mice. Proc. Natl Acad. Sci. USA 98, 10320-10325 (2001).
27. Adams, J. L., Badger, A. M., Kumar, S. & Lee, J. C. p38 MAP kinase: molecular target for the inhibition of proinfammatory cytokines. Prog. Med. Chem. 38, 1-60 (2001).
28. Lee, J. C., Griswold, D. E., Votta, B. & Hanna, N. Inhibition of monocyte IL-1 production by the anti-inflammatory compound SK&F 86002. Int. J. Immunopharmacol. 10, 835-843 (1988).
29. Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746 (1994).
30. Han, J., Lee, J. D., Bibbs, L. & Ulevitch R. J. A MAP kinase targetted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808-811 (1994).
31. Rouse, J. et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78, 1027-1037 (1994).
32. Freshney, N. W. et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78, 1039-1049 (1994).
33. Cuenda, A. et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364, 229-233 (1995).
34. Tong, L. et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Struct. Biol. 4, 311-316 (1997).
35. Eyers, P. A., Craxton, M., Morrice, N., Cohen, P. & Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. 5, 321-328 (1998).
36. Gum, R. J. et al. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP-binding pocket. J. Biol. Chem. 273, 15605-15610 (1998).
37. Mohammadi, M. et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276, 955-960 (1997).
38. De Azevedo, W. F. et al. Inhibition of cyclin-dependent protein kinases by purine analogues: crystal structure of human Cdk2 complexed with roscovitine. Eur. J. Biochem. 243, 518-526 (1997).
39. Gray, N. S. et al. Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors. Science 281, 533-538 (1998).
40. Ward, W. H. et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48, 659-666 (1994).
41. Fry, D. W. et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265, 1093-1095 (1994).
42. Osherov, N. & Levitski, A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur. J. Biochem. 225, 1047-1053 (1994).
43. Morin, M. J. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19, 6574-6583 (2000).
44. Senderowicz, A. M. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19, 6600-6606(2000).
45. Hoessel, R. et al. Indirubin, the active constituent of a chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biol. 1, 60-67 (1999).
46. Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104 (1996).
47. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561-566 (1996).
48. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. 344, 1031-1037 (2001).
49. Druker, B. J. & Lydon, N. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukaemia. J. Clin. Invest. 105, 3-7 (2000).
50. Schindler, T. et al. Structural mechanism of STI-571 inhibition of Abelson tyrosine kinase. Science 289, 1938-1942 (2000).
51. Buchdunger, E. et al. Abl protein-tyrosine kinase inhibitor, STI-571, inhibits in vitro signal transduction mediated by c-Kit and PDGF receptors. J. Pharmacol. Exp. Ther. 295, 139-145 (2000).
52. Joensuu, L. et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052-1056 (2001).
53. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J. & Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl Acad. Sci. USA 92, 7686-7689 (1995).
54. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T. & Saltiel, A. R. PD98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494 (1995).
55. Favata, M. F. et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623-18632 (1998).
56. Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810-816 (1999).
57. Brown, E. J. et al. Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature 377, 441-446 (1995).
58. Eyers, P. A., van den Ijssel, P., Quinlan, R. A., Goedert, M. & Cohen, P. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580 FEBS Lett. 451, 191-196 (1999).
59. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
60. Frame, S., Cohen, P. & Biondi, R. M. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7, 1321-1327 (2001).